Objective: To assess current practice in the pharmaceutical industry for assessing the potential for QT interval prolongation by non-cardiovascular medicinal products. Methods: The survey was based on responses from the Toxicology and (Safety) Pharmacology laboratories (a total of 74 laboratories) of 54 companies based in Europe, Japan /Asia and the USA, received between January and March 1999. Results: All 54 companies conducted preclinical in vivo electrocardiography (EGG) evaluation of new active substances (NASs). Thirty of these companies also conducted in vitro cardiac electrophysiology studies on their compounds. The majority of in vivo work was done in conscious beagle dogs. There was no consistency within the industry in defining the magnitude of change in QT interval that is considered biologically important. Most companies considered a change greater than 10% to be important, although the design of the studies suggested that group sizes used may not give sufficient statistical power to detect this size of change. Bazett's formula was used by 41% of laboratories to correct QT for changes in heart rate, despite the fact that this formula is generally deemed to be unsuitable for use in dogs. For studies in anaesthetised dogs, the majority of laboratories used barbiturate anaesthesia, but researchers should be aware of the effects of this and some other anaesthetic agents on QT interval. As for in vitro cardiac electrophysiology, there was wide diversity in the testing methodologies, particularly with regard to the test species and tissue type. As with QT prolongation, there was no consensus on the degree of action potential prolongation to cause concern. For both in vitro and in vivo testing, the majority of companies tested a minimum of three dose (or concentration) levels in order to ascertain any dose-response relationship. Conclusions: The survey provides a snapshot of the practice in the industry prior to any internationally-agreed consensus on the most effective and efficient approaches to minimising the risk of QT prolongation by new drugs in man. It must be stated that for any given methodology, the 'majority view' in the industry is not necessarily best practice.
Introduction
nal Products (CPMP) to issue a 'Points to Consider' document in 1997 [1] . There has since been much debate The occurrence of torsade de pointes with various nonwithin the pharmaceutical industry as to the most prediccardiovascular agents such as terfenadine, terodiline and tive in vitro and in vivo techniques to detect such activity, cisapride prompted the Committee for Proprietary Mediciand indeed as to whether the in vitro tests are worthwhile. This paper contains the results of a survey conducted in (NASs), prior to human exposure. The survey was not Rat 19 designed to ask opinions on the merits of the various Cynomolgus 24 CPMP-recommended tests. The survey involved two ques- Marmoset 2 tionnaires, on cardiac electrophysiology techniques in vivo and in vitro, respectively. Where we have made recommendations, they are based Pig / piglet 2 on our own experience of the methodology and knowledge Rabbit 3 of the literature.
Total 128 a Not mutually exclusive.
Methods
The 'in vivo' and 'in vitro' questionnaires comprised 28 rapid component of the delayed rectifying potassium and 38 primary questions, respectively. Copies of the current) -see Summary and recommendations. However, original questionnaires are available on request to the only one laboratory in the survey used the rat exclusively corresponding author. In the tables, 'Number' refers to for deriving ECG data, but another laboratory within the 'Number of laboratories'. Where percentages are given, same company was using non-rodents. The majority of these have been rounded-off to the nearest whole number.
laboratories evaluated ECGs from conscious dogs or monkeys. Regardless of species, telemetry techniques were used by 28 out of 74 laboratories (38%) ( Table 2 ).
Results
Of those companies using anaesthetised preparations, the majority (51%) used intravenous barbiturate as the A total of 54 companies responded, ranging from small anaesthetic of choice. Most of the anaesthetics recorded in private companies to large multinationals. Although this the survey have either overt or subtle effects upon carmight give undue influence to smaller companies (with a diovascular function, and many also increase QT interval smaller number of annual submissions to regulatory au-(see Summary and recommendations). According to the thorities), on the other hand the larger companies generally survey returns, 11 laboratories relied entirely on anaesthereturned responses from more than one site. Of the global tised preparations for evaluation of effects of NASs on the top 25 pharmaceutical companies worldwide in terms of ECG. Pharma sales in 1998 [2] , all companies ranked in the top five responded, and a total of 16 of the top 25 responded.
Experimental design
The majority of laboratories (72%) tested three or more 3.1. In vivo electrocardiogram (ECG) data dose levels. Surprisingly, several laboratories (17%) used only one or two dose groups, although no information to Where clearly indicated on the completed quesjustify this (such as vaccine evaluation) was given. tionnaires, the entries were separated into (Safety) Pharma-
The group sizes used predominantly ranged between cology and Toxicology Laboratories. Therefore, from a three and six with very few using group sizes below three total of 54 companies, there were responses from 74 (Table 3) . Of the 69 laboratories that used three or more laboratories. Nearly half of the laboratories (35) were animals per dose group, 44 (64%) applied statistical European-based although adequate representation from analysis to the QT interval data. However, in one laboraJapan (26) and the USA (13) give confidence that the responses reflect practices worldwide. tory, statistics on QT interval (see later in report) were apparently applied to a group size of two! The majority of laboratories (70%) included a negative Although this may cause difficulty in interpretation of control group of similar size to the test groups. The reason waveform morphology [3] , it is unlikely to have major for the lack of controls in the remainder is not apparent but consequences for measurement of EGG intervals. The may be due to experimental design with animals acting as importance of heart rate was probably not being addressed their own control.
adequately, with 32% of companies taking no measures to Of those laboratories that conducted multiple dose ensure that heart rate was recorded at 'resting' heart rate studies, the majority (86%) recorded ECGs both pre-and (Fig. 3) . post-dose. Those who did not (recording either pre-or
Eighteen laboratories recorded EGG at paper speeds of post-dose only) all used concomitant negative controls. 25 mm / s or less although, of these, only 7 relied on Post-dose recordings were usually timed to relate to manual measurement and could be expected to have had toxicokinetic / pharmacokinetic profiles of the NAS (Figs. 1 difficulty with accuracy of measurement. Similarly, 8 and 2).
laboratories appeared to use a 1 mm / mV amplitude calibration which could be expected to cause difficulty with 3.1.3. Techniques assessment of waveform, especially T-wave. There was wide variability between laboratories in the The majority of laboratories (73%) did not use chest positioning of animals for EGG recording (Table 4) .
leads. Most laboratories recorded six limb leads, presumably to assess morphology (Table 5) . Twenty-nine laboratories used either lead II alone or in combination with leads I and III. However, the majority of laboratories (78%) measured EGG intervals from lead II only (Table  6) . Automated EGG data capture and analysis was widely used (Fig. 4) . The majority of these laboratories had validated their data acquisition systems, reflecting a similar proportion conducting their studies in a 'Good Laboratory Practice' (GLP) environment (Fig. 5) .
Despite the fact that 69% of laboratories used validated sion. The use of formulae to correct QT for changes in heart rate ( Fig. 6 ) was widespread (63% of laboratories), and There were 4 types of analysis used by laboratories to Longest measurement from all leads 4 5 assess drug-induced changes in QT (Table 8 ). However, of Other 6 8 possible concern is that 26% of laboratories did not appear interval. For those that have established criteria variability in the method of assessment exist (Table 9) . Thirteen laboratories considered a 10% increase in QT interval to be significant (i.e. biologically significant) with a wide range of 'thresholds for concern' amongst the remaining laboratories.
In vitro cardiac electrophysiological data
In contrast to the in vivo section of the survey, none of the companies in the survey performed in vitro cardiac electrophysiology in more than one in-house facility, so the term 'company' rather than 'laboratory' is used in this section. Of the 54 companies polled, 30 (56%) conducted in vitro cardiac electrophysiology studies, and a further 5 (9%) planned to do so (Fig. 7) . methods (manual or automatic), only 53% had acceptance / The data presented here are based on replies from the 30 rejection criteria based on trace quality. The methodology companies that did carry out such studies at the time of the used to record ECG data has been changed significantly in survey. Of these 30 companies, 20 had the capability to the last 5-10 years in 39 laboratories (i.e. 52%). This perform the studies in-house. Most of the 30 companies included 17 of the 25 laboratories that have experienced were located in Europe (53%), with fewer in Japan /Asia regulatory issues with compounds that prolong QT interand the USA (30% and 17%, respectively). The geographival.
cal distribution of companies that had in-house capability to carry out in vitro cardiac electrophysiology showed approximately 20% to be located in the USA, with 40% each in Japan /Asia and Europe. The majority (67%) of the 30 companies conducted these in vitro investigations prior to first administration to man.
Species and tissues
There was a broad diversity between companies in the choice of species and tissues used for these studies. The most commonly used tissues were Purkinje fibre and papillary muscle. The distribution of tissues and species is shown in Fig. 8 . A small number of companies reported animal will diminish when tissues are removed for in vitro studies.
Experimental design
There was no consensus on criteria for selection of a concentration range for the test compound (Fig. 9) . Thirtyseven per cent of companies tested multiples of a plasma Table 9 Magnitude of change in OT interval considered to be significant Number (i) % change in QT Fig. 6 . Correction of QT for heart rate.
. The percentage of companies that used negative and positive controls in their studies is shown in Fig. 12 . It is noteworthy that while 57% of respondents included negative controls, 37% did not. It is of less concern that 30% did not run a positive control group. Where control groups (positive or negative) are used, they generally consist of three to six preparations.
Regarding timing of electrophysiology recordings, 60% of companies used pre-selected or specified times, while the remainder used variable time points, or did not answer this question. In 60% of companies, the identity of key metabolites was not known at the time of initial studies, so where they were tested at all (in 53% of companies) this was done at a later time.
Most companies (63%) acquired their action potential recordings by continuous impalement of the tissue, but 20% used serial sampling (i.e. successive impalement of several cells during the experiment). Slightly over half the companies (57%) used a 'normal' stimulation frequency (in this context, 'normal' is taken to be 1 Hz) while 27% used low and / or high frequencies in addition. Again, 57% used more than one frequency of stimulation in their study concentration (therapeutic or pharmacologically effective), design; 65% allowed an adjustment period of 1 to 5 min whereas in 30% of companies a fixed range of confollowing any change in stimulation frequency, whereas centrations was used, irrespective of the potency of the others used 6 to 10 min (12%), or greater than 10 min compound. Most companies tested between three and six (6%). The majority of companies (70%) used either concentrations of test compound, in three to six preparaTyrodes, Krebs or Krebs-Henseleit solutions in their tions per compound (Figs. 10 and 11) . Generally, the species used were appropriate to detect QT change of relevance to man, with beagle dogs being the most popular. Other species were used less frequently studies, and the concentrations of potassium, magnesium, than the dog, but with the exception of the rat, there is no calcium and glucose used reflected this. Most companies particular reason why other species such as pig / minipig, used a temperature over 358C, but some (13%) used a rabbit or guinea-pig would not be as predictive of effects temperature below 358C.
on ventricular repolarisation in man. However, the rat should not be used to assess QT interval changes. Whereas 3.
Data analysis and interpretation
the rat is of some value in cardiovascular assessments, this Most of the key action potential parameters were species will probably not be susceptible to action potential measured and / or analysed by the majority of companies, lengthening and QT prolongation as a consequence of including, importantly, resting membrane potential, maxiblockade of the rapid component of the delayed rectifying mum upstroke velocity, amplitude and action potential potassium current (I ). Although the consensus view is Kr duration at 90% repolarisation (APD ). Probably the that ventricular tissue from this species does express this 90 single most important parameter to be measured in order to ion channel protein [7, 8] , a dominant transient outward assess activity at the I channel is APD . The range of current (I ) will rapidly restore membrane potential to Kr 90 to control values obtained for this parameter is shown in negative voltages, thus reducing the time for I activation.
Kr Table 10 . As a consequence, the adult rat lacks a prominent action However, 13% of companies did not appear to measure potential plateau and therefore agents blocking I will not Kr APD , and there were differences in what degree of prolong action potential duration in this species [7, 9, 10] . In 90 change in APD companies thought was a 'cause for short, the current patterns during repolarization are quite 90 concern' (Fig. 13) . This varied from ,10% (by 10% of different in the rat myocardium compared with humans companies), 10-20% (by 47% of companies) to .20% (by and other mammalian species, such as guinea-pig [11, 12] . 10% of companies). It may also be of some concern that, in 17% of companies, data were not subject to peer review.
Choice of anaesthetic ( for EGG measurements in
Finally, nearly half of the companies stated that they had anaesthetised preparations) changed the methods that they used for in vitro elecAnaesthetised preparations are an acceptable adjunct to trophysiology studies over the past 5 to 10 years, but it did the conscious studies, permitting a more thorough evaluanot seem that this was related to any particular experience tion of cardiovascular effects. Choice of anaesthetic is with the regulatory authorities.
important, as several agents in common use have direct effects on QT interval or the cardiovascular system (Table  11 ).
Summary and recommendations
It is, therefore, worth noting that the presence of anaesthetic during cardiovascular evaluations may alter the For both in vitro and in vivo testing, the majority of sensitivity of the model to detect effects on ventricular companies tested a minimum of three dose (or concenrepolarisation and consequently QT duration. Consideration should be given to the effects of the anaesthetic agent used on the cardiovascular system and on cardiac ion channels, particularly when anaesthetised preparations are to be the only model for ECG assessment.
EGG leads
The number of leads used to collect ECG data varied between laboratories. We propose that only one lead (generally lead II) is necessary for measuring QT interval, but that the recording of three leads will enable choice of the clearest waveform for interval measurements, and will permit assessment of morphology. Chest leads are not required for ECG interval analysis. Few laboratories assessed U-wave, probably reflecting its rare occurrence in 90 
Propofol1alfentanil
Hypotension during induction No effect in man [26] ; no literature but normotensive thereafter [18, 19] found indicating an effect in dogs Urethane Hypotension, release of adrenoNo literature found indicating an medullary catecholamines [20, 21] effect (in any species)
dogs. The large majority of laboratories in the survey did numbers to detect the magnitude of changes in QT interval not measure QT interval dispersion. There is little pubthat they consider to be 'biologically significant'. Based on lished data to support the value of QT dispersion in preliminary estimates of sample sizes, using a standard animals presently.
formula for power calculations [16] we believe that group sizes of n54 may be inadequate to detect changes in QT 4.1.4. Quality of data interval of 10% in conscious dogs, but may detect changes Methodology used to evaluate ECG in animals is of |20% (for control QT5200 ms; control S.D.519 ms; evolving. Some of the improvements appear to be in P,0.05, 2-tailed, unpaired test; 80% power). This can be response to regulatory issues and recent guidelines. Generimproved upon if QT is corrected using the formula of Van ally, the quality of data generated is considered to be de Water et al. (1989) , where group sizes of five are adequate to permit evaluation of drug-induced changes in sufficient to detect changes in QTc of 10% (control QTc5 QT interval. Wide variability existed in the positioning of 236 ms; control S.D.513 ms; P,0.05, 2-tailed, unpaired dogs for EGG recording, although we do not consider this test; 80% power). However, the degree of change in QT to be important for measuring ECG intervals per se.
(or QTc) considered to be 'biologically significant' was not universally consistent. Not all laboratories used statistical 4.1.
Correction of QT interval for changes in heart
analysis of their QT data. We consider a lack of statistical rate analysis to be undesirable. Whereas 41% of laboratories used Bazett's formula to correct QT for changes in heart rate, in the literature this 4.2. In vitro techniques formula is generally deemed to be unsuitable for use in dogs. Use of correction formulae was not consistent and in
Only 30 companies investigated their compounds using some instances inappropriate. In those cases where a in vitro cardiac electrophysiology tests. There was wide statistically significant change in heart rate is seen, QT diversity in the testing methodologies, particularly with should be corrected and the method of correction must be regard to the test species and tissue type. The survey was justified. Bazett's formula is unlikely to be suitable for initiated in response to the CPMP Points to Consider [1] dogs, and other methods of correction have been proposed which did not include assessment of activity in cloned [13] [14] [15] . Alternatively, a regression approach may be human ion channels. It is recognised that this methodology applied, based on in-house data of QT-heart rate relationis becoming increasingly important. ships in the individual beagles under drug-free conditions. Measures should be taken to ensure that, as far as possible, 4.2.1. Choice of species recordings are taken at 'resting' heart rates. This will As with the in vivo testing, there is no compelling reduce the need for correction formulae, reduce the reason to use one species rather than another on the basis variance of the data, and ensure that QT prolongation is of ion channel function, with the exception of the rat, not masked at high heart rates by the effects of reverse which is of limited value for predicting electrophysiologiuse-dependence.
cal effects on the human myocardium, and was not in any case used for in vitro studies by any of the companies in 4.1.6. Study design /power the survey. ECG recording / analysis was usually conducted at intervals that reflected pharmacokinetic / toxicokinetic profiles.
Tissue preparation The study designs are generally acceptable with respect to
The use of in vitro techniques may require that the numbers of dose groups, although a minimum of three experimental tissue be removed under terminal anaesdose levels is required to detect dose-related changes.
thesia, often using a high dose of barbiturate. This is Investigators need to perform statistical power calculations especially true in the case of larger species such as the dog, based on in-house data, in order to build-in sufficient n which cannot reasonably be killed by any other method. It is not established whether, or how rapidly, the effects of an 5. Conclusions anaesthetic administered to the intact animal will wear off once tissue has been removed into an organ bath and
The survey provides a snapshot of the practice in the bathed with a physiological salt solution. Therefore, there pharmaceutical industry prior to any internationally-agreed would have to be some degree of caution implicit in the consensus on the most effective and efficient approaches to use of tissue harvested from anaesthetised animals (and minimising the risk of QT prolongation by new drugs in thus from dogs).
man. The survey has revealed a wide spectrum of approaches to addressing this issue in the pharmaceutical industry, and there is clearly a need for a degree of 4.2.3. Action potential characteristics consensus on 'best practice' in terms of methodology We recommend that APD is the most appropriate [27, 28] . It must be stated, however, that for any given 90 marker of action potential duration. However, careful methodology, the 'majority view' in the industry is not evaluation of drug effects on V and upstroke amplitude necessarily best practice. max is as important as assessment of APD. As with QT prolongation, there was no consensus on the degree of action potential prolongation to cause concern.
